Sweetening Pharmaceutical Radiochemistry by <sup>18</sup>F-Fluoroglycosylation: Recent Progress and Future Prospects

In the field of <sup>18</sup>F-chemistry for the development of radiopharmaceuticals for positron emission tomography (PET), various labeling strategies by the use of prosthetic groups have been implemented, including chemoselective <sup>18</sup>F-labeling of biomolecules. Am...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sandip S. Shinde, Simone Maschauer, Olaf Prante
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
PET
R
Accès en ligne:https://doaj.org/article/8f9d379a10724a7bad6cf05af0b0f11d
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:In the field of <sup>18</sup>F-chemistry for the development of radiopharmaceuticals for positron emission tomography (PET), various labeling strategies by the use of prosthetic groups have been implemented, including chemoselective <sup>18</sup>F-labeling of biomolecules. Among those, chemoselective <sup>18</sup>F-fluoroglycosylation methods focus on the sweetening of pharmaceutical radiochemistry by offering a highly valuable tool for the synthesis of <sup>18</sup>F-glycoconjugates with suitable in vivo properties for PET imaging studies. A previous review covered the various <sup>18</sup>F-fluoroglycosylation methods that were developed and applied as of 2014 (Maschauer and Prante, BioMed. Res. Int. 2014, 214748). This paper is an updated review, providing the recent progress in <sup>18</sup>F-fluoroglycosylation reactions and the preclinical application of <sup>18</sup>F-glycoconjugates, including small molecules, peptides, and high-molecular-weight proteins.